Background {#Sec1}
==========

The infection with human papillomavirus (HPV) is strongly associated with genital disease. Type-specific persistent infection with high-risk (HR) HPV is the major reason of cervical squamous intraepithelial lesions as well as cervical cancer \[[@CR1]--[@CR3]\]. According to its relationship with cervical cancer and precancerous lesions, HPV genotypes are divided into HR-HPV and low-risk (LR) HPV genotypes \[[@CR4]\]. These different HPV genotypes have different pathogenicity \[[@CR5]\]. The HR-HPV genotypes may lead to cervical carcinogenesis, while the LR-HPV are associated with benign or low-grade changes in cervical cells, such as genital warts \[[@CR6], [@CR7]\].

There are many reports on the prevalence of HPV in different populations. The prevalence of HPV infection varies greatly by country, region within country, and population \[[@CR8], [@CR9]\]. Therefore, understanding the prevalence characteristics of HPV in different regions is very important for the early detection and prevention of local cervical cancer. In the present study, we made a comprehensive analysis of the prevalence characteristics of HPV in both outpatient women and healthy women who were recruited from Jiangsu, China.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

The women who received HPV screening at Nanjing KingMed Diagnostics between January of 2016 and May of 2017 were recruited. We excluded the women who did not have valid testing results (e.g., the unsuccessful test as a result of unqualified sampling) or who were not the residents of Jiangsu Province. Finally, we enrolled 65,613 women aged 16--85 years, including 45,736 outpatients and 19,877 healthy women who received routine examination. All the data were retrospectively collected from Laboratory Information Management System of Nanjing KingMed Diagnostics.

Specimen collection {#Sec4}
-------------------

All the participants were asked to do not douche or use tampons or vaginal creams, deodorants, or medications for 2 days before the test. The participants were not in menstruation period and refrained from sex for 48 h before the test. The cervico-vaginal cells were collected from the transformation zone of the uterine cervix by a gynecologist or a trained physician using a standard cytobrush, then suspended in a standard transport medium (STM) for the Tellgenplex™ HPV DNA Test (Tellgen Life Science Co., Shanghai, China) and stored at 4 °C until analyzed (24 h--72 h) \[[@CR10]\].

HPV genotyping {#Sec5}
--------------

HPV types were detected using the Tellgenplex™ HPV DNA Test (Tellgen Life Science Co. Ltd., Shanghai, China). It could identify the 27 most common HPV genotypes including 14 HR-HPV genotypes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and 13 LR-HPV/undetermined risk (UR-) HPV genotypes (6, 11, 26, 40, 42, 43, 44, 53, 61, 81, 82, 83). Briefly, DNA was extracted, then 100 ng HPV DNA was used as template and added into 20 μl reaction mixture that includes 10 μl PCR premixed solution, 0.8 μl Taq DNA Polymerase and 5 μl primer mixture.

Statistical analysis {#Sec6}
--------------------

The SPSS version 19.0 (IBM, Armork, NY, USA) was used to perform all statistical analyses. HPV prevalence rate was estimated by a proportion and summarized as a percentage, with an exact binomial 95% confidence interval (95% CI). Prevalence estimates are presented overall and by age (\< 20 years, 20--29 years, 30--39 years, 40--49 years, 50--59 years and ≥ 60 years). The chi-squared (*x*^*2*^) was used to test for departure from homogeneity in prevalence across all the 6 age groups. The prevalence was estimated separately for outpatients and healthy women. We used data of healthy women to estimate percentage of women who will be protected by the vaccines targeting different HPV types. *p* \< 0.05 was considered statistically significant.

Results {#Sec7}
=======

The overall prevalence of HPV infection {#Sec8}
---------------------------------------

In the 45,736 outpatient women, 8081 participants (17.7, 95% CI: 17.3--18.0%) were infected with at least one HPV type, including 6253 participants (13.7, 95% CI: 13.4--14.0%) infected with a single HPV type and 1828 participants (4.0, 95% CI: 3.8--4.2%) infected with multiple HPV types (*P* \< 0.001). The HR-HPV prevalence rate (15.7, 95% CI: 15.3--16.0%) was higher than the LR/UR-HPV rate (7.4, 95% CI: 7.2--7.7%) (Table [1](#Tab1){ref-type="table"}).Table 1The prevalence of HPV infection in all the specimensMultiple infection (%)ParticipantsTotal (%)HR-HPV (%)LR/UR-HPV (%)Single (%)Dual3 or MoreOutpatient women8081(17.7)7160(15.7)3405(7.4)6253(13.7)1336(2.9)492(1.1)Healthy women2110(10.6)2002(10.1)611(3.1)1696(8.5)335(1.7)79(0.4)*P*000000

Regarding 19,877 healthy women, 8.5% (95% CI: 8.1--8.9%) were infected with single HPV subtype, whereas 2.1% (95% CI: 1.9--2.3%) were infected with multiple HPV subtypes (*P* \< 0.001). HR-HPV and LR/UR-HPV infection was detected in 2002 (10.1, 95% CI 9.7--10.5%) and 611 (3.1, 95% CI: 2.8--3.3%) healthy women, respectively (Table [1](#Tab1){ref-type="table"}). We estimated percentage of women who will be protected by the vaccines targeting different HR-HPV types. The estimates are presented in Additional file [1](#MOESM1){ref-type="media"}: Table S1. We further analyzed the distribution of HPV types in HPV-positive specimens. The top ten HPV types are presented in Table [2](#Tab2){ref-type="table"}. The two most commonly detected HPV types were HPV 16 and 58 regardless of single- or multiple-type infection or source of the participants.Table 2The prevalence of the top ten frequences of HPV type of the single/multiple infection in the outpatient and healthy womenInfection TypeOutpatient womenHealthy womenHPV TypenPrevalence rate (95% CI)HPV TypenPrevalence rate (95% CI)Single infectionHPV16101812.6 (11.9--13.3)HPV581949.2(8.0--10.4)HPV587028.7(8.1--9.3)HPV161878.9(7.6--10.1)HPV525887.3(6.7--7.8)HPV521466.9(5.8--8.0)HPV533384.2(3.7--4.6)HPV531225.8(4.8--6.8)HPV393214.0(3.5--4.4)HPV391055.0(4.0--5.9)HPV182853.5(3.1--3.9)HPV611055.0(4.0--5.9)HPV612783.4(3.0--3.8)HPV56864.1(3.2--4.9)HPV562563.2(2.8--3.5)HPV81823.9(3.1--4.7)HPV812473.1(2.7--3.4)HPV59743.5(2.7--4.3)HPV512272.8(2.4--3.2)HPV51733.5(2.7--4.2)Multiple infectionHPV164155.1(4.7--5.6)HPV16984.6(3.7--5.5)HPV584065.0(4.5--5.5)HPV58944.5(3.6--5.3)HPV523634.5(4.0--4.9)HPV53753.6(2.8--4.3)HPV532663.3(2.9--3.7)HPV52653.1(2.3--3.8)HPV392433.0(2.6--3.4)HPV39602.8(2.1--3.6)HPV562072.6(2.2--2.9)HPV61562.7(2.0--3.3)HPV612052.5(2.2--2.9)HPV56482.3(1.6--2.9)HPV181912.4(2.0--2.7)HPV66482.3(1.6--2.9)HPV811912.4(2.0--2.7)HPV51432.0(1.4--2.6)HPV511882.3(2.0--2.7)HPV43422.0(1.4--2.6)

The prevalence of multiple HPV infection {#Sec9}
----------------------------------------

In the outpatient women, there were 1336 participants infected with dual HPV types and 492 participants infected with three or more HPV types (Table [1](#Tab1){ref-type="table"}). In healthy women, there were 335 participants infected with dual HPV types and 79 participants infected with three or more HPV types (Table [1](#Tab1){ref-type="table"}). Table [3](#Tab3){ref-type="table"} presents the top ten combinations of HPV types in the participants. The top three most common combinations of the types were HPV16 + 58, HPV52 + 58 and HPV39 + 52 for outpatient women and HPV16 + 52, HPV52 + 58 and HPV39 + 58 for the healthy women (Table [3](#Tab3){ref-type="table"}). The detailed distributions of multiple HPV infection are presented in Additional file [2](#MOESM2){ref-type="media"}: Table S2.Table 3The top ten multiple HPV infection mode in participantsOutpatient womenHealthy womenCombination of typesnPrevalence rate (95% CI)Combination of typesnPrevalence rate (95% CI)16 + 58442.4(1.7--3.1)16 + 52112.7(1.1--4.2)52 + 58331.8(1.2--2.4)52 + 58112.7(1.1--4.2)39 + 52211.1(0.7--1.6)39 + 5892.2(0.8--3.6)52 + 61191.0(0.6--1.5)53 + 5881.9(0.6--3.3)16 + 39191.0(0.6--1.5)16 + 5881.9(0.6--3.3)18 + 58181.0(0.5--1.4)35 + 5361.4(0.3--2.6)16 + 56160.9(0.4--1.3)16 + 5161.4(0.3--2.6)16 + 33150.8(0.4--1.2)16 + 3551.2(0.2--2.3)16 + 53150.8(0.4--1.2)16 + 6651.2(0.2--2.3)33 + 58150.8(0.4--1.2)58 + 6151.2(0.2--2.3)

The prevalence of HPV infection in different age groups {#Sec10}
-------------------------------------------------------

We analyzed the distribution of positive HPV results in different age groups. Our results showed that the under 20 age group owned the highest rate of HPV infection (36.7, 95% CI: 32.2--41.2%), followed by the over 60 age group (25.6, 95% CI: 23.3--27.9%), while the 30--39 age group had the lowest prevalence rate (17.0, 95% CI: 16.4--17.6%) in the outpatient women (*P* \< 0.001). In the healthy women, people aged 50--59 years had the highest prevalence rate (12.4, 95% CI: 11.1--13.6%) and the 30--39 age group had the lowest prevalence rate (9.9, 95% CI: 9.3--10.6%) (*P* \< 0.001) (Table [4](#Tab4){ref-type="table"}).Table 4Prevalence of HPV infection in different age groupsOutpatient WomenHealthy WomenAge groupsn (postive/total)Prevalence rate (95% CI)n (postive/total)Prevalence rate (95% CI)\< 20164/44736.7(32.2--41.2)0/0020--291733/988617.5(6.8--18.3)327/309810.6 (9.5--11.6)30--392325/1367117.0(16.4--17.6)822/82939.9 (9.3--10.6)40--492468/1233920.0(19.3--20.7)522/481910.8(10.0--11.7)50--591032/552418.7(17.7--19.7)332/268412.4 (11.1--13.6)≥60359/140125.6(23.3--27.9)107/98310.9 (8.9--12.8)P00.01

We further analyzed the prevalence of single and multiple HPV infections in different age groups. In the outpatient women, the peak prevalence for both single and multiple HPV infection was observed in the participants aged \< 20 years. The lowest prevalence of single HPV infection in outpatients was observed in 20--29 age group, while the lowest prevalence of multiple HPV infection was observed in 30--39 age group. However, it was different from those of the healthy women where the highest prevalence of single HPV infection was observed in 50--59 age group and the lowest was in the over 60 age group. Regarding dual HPV infection in healthy women, the highest and lowest prevalence was respectively observed in the over 60 age group and the 30--39 age group (Table [5](#Tab5){ref-type="table"}).Table 5Prevalence of single and multiple HPV infections in different age groupsAge groupsOutpatient WomenHealthy WomenTotalSingle (%)Dual (%)3 or more (%)TotalSingle (%)Dual (%)3 or more (%)\<2044790 (20.1)42 (9.4)32 (7.2)000020-2998861267 (12.8)330 (3.3)136 (1.4)3098248 (8.0)67 (2.2)12 (0.4)30-39136711859 (13.6)368 (2.7)98 (0.7)8293676 (8.2)112 (1.4)34 (0.4)40-49123391991 (16.1)362 (2.9)115 (0.9)4819429 (8.9)74 (1.5)19 (0.4)50-595524788 (14.3)173 (3.1)71 (1.3)2684266 (9.9)55 (2.0)11 (0.4)≥601401258 (18.4)61 (4.4)40 (2.9)98377 (7.8)27 (2.7)3 (0.3)*P*0000.0310.0010.992

Discussion {#Sec11}
==========

Epidemiological studies had shown that persistent cervical HR-HPV infection is correlated with an increased risk of developing a high-grade cervical intraepithelial lesion (e.g., cervical cancer) \[[@CR11]\]. Fortunately, the successful development of HPV vaccines would help to prevent the occurrence of cervical cancer. Population-based epidemiological data would assist to develop HPV vaccines for a specific population.

Most of the previous researches on HPV epidemiology were only based on outpatient samples. Since the outpatients usually come to the hospital for some medical problems, the HPV prevalence is different from that of healthy women who participate in normal medical examinations. In our study, both outpatients and healthy participants were recruited from Jiangsu, China. In the 45,736 outpatient women, the prevalence of HPV was 17.7% and the HR-HPV prevalence was 15.7%. Compared with similar studies in China, the prevalence in our study was higher than that in Beijing (9.9%) \[[@CR12]\] and Yunnan (12.9%) \[[@CR13]\], but lower than that in Fujian (38.3%) \[[@CR14]\] and Zhejiang (20.54%) \[[@CR15]\]. The different HPV prevalence might be explained by different economic conditions, cultural diversity, geographical regions and survey period. Regarding the 19,877 healthy women, the overall HPV prevalence and HR-HPV prevalence was 10.6 and 10.1%, respectively. It was fully explained that more attention should be paid to the healthy women infected with HR-HPV.

The analysis of HPV prevalence showed that the most commonly identified HR-HPV genotypes were HPV 16, 58, 52, 39 and 18 among the outpatient women. It was different from the healthy women, where HPV 58, 16, 52, 39 and 56 were the five most commonly detected HR-HPV genotypes. The present study showed that HPV16, 58 and 52 were the top three detected HR-HPV genotypes in the two populations, which was similar to the other studies conducted in China, despite the prevalence varied widely \[[@CR13], [@CR16], [@CR17]\]. However, it was different from the result of a meta-analysis which summarized global reports and indicated that HPV16, 18 and 45 were most commonly detected genotypes \[[@CR18]\]. With a relatively lower prevalence for HPV 18, the vaccines against HPV16, 58 and 52 should be developed for Chinese women.

In the outpatient women with multiple HPV infection, the most commonly identified combinations of HPV types were HPV16 + 58, HPV52 + 58 and HPV39 + 52. While the top three combinations of types were HPV16 + 52, HPV52 + 58 and HPV39 + 58 for the healthy women. It was easy to note that these top three multiple-type infections were the different combinations of HPV 16, 39, 52 and 58. We also found that the vaccines targeting HPV 16/39/52/58 will protect more women in East China, when four HPV types were included in vaccines (Additional file [1](#MOESM1){ref-type="media"}: Table S1). If three HPV types were included, HPV 16, 52 and 58 were the recommended combination. When two HPV types were included, HPV 16 and 58 were the recommended combination. 4.6, 3.9 and 2.9% women will be protected by vaccines targeting HPV 16/39/52/58, HPV 16/52/58, and HPV 16/58, respectively. Because the 2v, 4v, and 9v HPV vaccines on the market do not provide protection against type 39, and the different prevalence of HPV types was observed between women in China and the other countries, it is necessary to develop HPV vaccines specific for Chinese women. The HPV vaccines that covered the four additional HR-HPV types (HPV16/39/52/58) may be more meaningful for a HPV vaccination program in China.

The peak prevalence rate of overall HPV, single HPV and HR-HPV was observed in healthy women aged 50--59 years. This was very different from the findings in outpatients of China. Previous studies have reported that HPV prevalence had two peaks in terms of age, while the peak age varied in different studies \[[@CR19]--[@CR21]\]. The two peaks were generally found in younger and menopausal women. Wang et al. found that HR-HPV infection showed higher rates in younger groups and lower rates in middle age groups and the highest prevalence in individuals aged 15--19 years \[[@CR22]\]. Tang et al. reported that individuals aged 21--40 years had highest HPV prevalence \[[@CR23]\]. Our data suggested that the highest HPV prevalence was found in outpatient women at the ages of \< 20 or ≥ 60 years.

Conclusion {#Sec12}
==========

In the present study, we presented the data on the prevalence characteristics of HPV in both outpatient women and healthy women who were recruited from Jiangsu province, east of China. Such data could guide interventions to control prevalence of HPV. Vaccines against HPV58/16/52/39 should be developed for Chinese women specifically. 50--59 years old women had highest HPV prevalence and should be paid more attention.
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Additional file 1:**Table S1.** The estimated percentage of women who will be protected by the vaccines targeting different HR-HPV types (XLSX 56 kb) Additional file 2:**Table S2.** The all multiple HPV infection mode in participants. (XLSX 29 kb)
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